Table 1 Cohort characteristics
Sex | Australia | China | Germany | Greece | Italy | Lebanon | New Zealand | Philippines | UK | Vietnam | Other English-speaking | Other Non-English |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Reference | # | # | # | # | # | # | ||||||
Female | 7267 (43.8%) | 407 (47.3%) | 127 (36.7%) | 68 (13.2%) | 161 (20.9%) | 77 (20.9%) | 225 (50.1%) | 113 (55.9%) | 1028 (40.1%) | 110 (36.3%) | 177 (49.0%) | 1267 (33.5%) |
Male | 9328 (56.2%) | 454 (52.7%) | 219 (63.3%) | 447 (86.8%) | 611 (79.1%) | 292 (79.1%) | 224 (49.9%) | 89 (44.1%) | 1533 (59.9%) | 193 (63.7%) | 184 (51.0%) | 2513 (66.5%) |
Age at diagnosis | Reference | # | # | # | # | # | # | # | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median age (years) | 70 | 72 | 72 | 73 | 75 | 67 | 65 | 63 | 73 | 66 | 70 | 70 |
18–59 years | 3184 (19.2%) | 201 (23.3%) | 43 (12.4%) | 40 (7.8%) | 43 (5.6%) | 84 (22.8%) | 150 (33.4%) | 77 (38.1%) | 284 (11.1%) | 95 (31.4%) | 57 (15.8%) | 704 (18.6%) |
60–69 years | 4738 (28.6%) | 152 (17.7%) | 106 (30.6%) | 147 (28.5%) | 146 (18.9%) | 118 (32.0%) | 149 (33.2%) | 57 (28.2%) | 701 (27.4%) | 85 (28.1%) | 112 (31.0%) | 1075 (28.4%) |
70–79 years | 5281 (31.8%) | 280 (32.5%) | 116 (33.5%) | 211 (41.0%) | 338 (43.8%) | 116 (31.4%) | 109 (24.3%) | 37 (18.3%) | 875 (34.2%) | 69 (22.8%) | 129 (35.7%) | 1195 (31.6%) |
80+ years | 3392 (20.4%) | 228 (26.5%) | 81 (23.4%) | 117 (22.7%) | 245 (31.7%) | 51 (13.8%) | 41 (9.1%) | 31 (15.3%) | 701 (27.4%) | 54 (17.8%) | 63 (17.5%) | 806 (21.3%) |
SEIFA3 | Reference | # | # | # | # | # | # | # | # | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Quintile 1 | 5045 (30.4%) | 173 (20.1%) | 91 (26.3%) | 117 (22.7%) | 153 (19.8%) | 172 (46.6%) | 121 (26.9%) | 52 (25.7%) | 715 (27.9%) | 187 (61.7%) | 63 (17.5%) | 1047 (27.7%) |
Quintile 2 | 3965 (23.9%) | 198 (23.0%) | 83 (24.0%) | 137 (26.6%) | 162 (21.0%) | 92 (24.9%) | 100 (22.3%) | 40 (19.8%) | 569 (22.2%) | 65 (21.5%) | 55 (15.2%) | 810 (21.4%) |
Quintile 3 | 3137 (18.9%) | 184 (21.4%) | 69 (19.9%) | 130 (25.2%) | 171 (22.2%) | 58 (15.7%) | 74 (16.5%) | 51 (25.2%) | 475 (18.5%) | 24 (7.9%) | 70 (19.4%) | 740 (19.6%) |
Quintile 4 | 2412 (14.5%) | 141 (16.4%) | 58 (16.8%) | 93 (18.1%) | 195 (25.3%) | 29 (7.9%) | 79 (17.6%) | 34 (16.8%) | 415 (16.2%) | 14 (4.6%) | 80 (22.2%) | 581 (15.4%) |
Quintile 5 | 2036 (12.3%) | 165 (19.2%) | 45 (13.0%) | 38 (7.4%) | 91 (11.8%) | 18 (4.9%) | 75 (16.7%) | 25 (12.4%) | 387 (15.1%) | 13 (4.3%) | 93 (25.8%) | 602 (15.9%) |
Charlson score | Reference | # | # | # | # | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 12,472 (75.2%) | 742 (86.2%) | 270 (78.0%) | 399 (77.5%) | 575 (74.5%) | 285 (77.2%) | 362 (80.6%) | 171 (84.7%) | 1940 (75.8%) | 256 (84.5%) | 279 (77.3%) | 2994 (79.2%) |
≥ 1 | 4123 (24.8%) | 119 (13.8%) | 76 (22.0%) | 116 (22.5%) | 197 (25.5%) | 84 (22.8%) | 87 (19.4%) | 31 (15.3%) | 621 (24.2%) | 47 (15.5%) | 82 (22.7%) | 786 (20.8%) |
Year of diagnosis | Reference | # | # | # | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
2003–2004 | 2192 (13.2%) | 79 (9.2%) | 42 (12.1%) | 64 (12.4%) | 103 (13.3%) | 39 (10.6%) | 38 (8.5%) | 12 (5.9%) | 334 (13.0%) | 26 (8.6%) | 53 (14.7%) | 427 (11.3%) |
2005–2006 | 2188 (13.2%) | 93 (10.8%) | 47 (13.6%) | 62 (12.0%) | 122 (15.8%) | 35 (9.5%) | 48 (10.7%) | 27 (13.4%) | 371 (14.5%) | 39 (12.9%) | 46 (12.7%) | 484 (12.8%) |
2007–2008 | 2347 (14.1%) | 109 (12.7%) | 52 (15.0%) | 70 (13.6%) | 103 (13.3%) | 45 (12.2%) | 83 (18.5%) | 31 (15.3%) | 387 (15.1%) | 32 (10.6%) | 31 (8.6%) | 532 (14.1%) |
2009–2010 | 2444 (14.7%) | 110 (12.8%) | 54 (15.6%) | 86 (16.7%) | 115 (14.9%) | 52 (14.1%) | 58 (12.9%) | 28 (13.9%) | 408 (15.9%) | 48 (15.8%) | 68 (18.8%) | 560 (14.8%) |
2011–2012 | 2431 (14.6%) | 136 (15.8%) | 53 (15.3%) | 73 (14.2%) | 109 (14.1%) | 57 (15.4%) | 71 (15.8%) | 29 (14.4%) | 381 (14.9%) | 41 (13.5%) | 40 (11.1%) | 581 (15.4%) |
2013–2014 | 2474 (14.9%) | 162 (18.8%) | 45 (13.0%) | 78 (15.1%) | 111 (14.4%) | 82 (22.2%) | 82 (18.3%) | 31 (15.3%) | 333 (13.0%) | 55 (18.2%) | 57 (15.8%) | 569 (15.1%) |
2015–2016 | 2519 (15.2%) | 172 (20.0%) | 53 (15.3%) | 82 (15.9%) | 109 (14.1%) | 59 (16.0%) | 69 (15.4%) | 44 (21.8%) | 347 (13.5%) | 62 (20.5%) | 66 (18.3%) | 627 (16.6%) |
Extent of disease | Reference | # | # | # | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Localised | 3073 (18.5%) | 138 (16.0%) | 51 (14.7%) | 81 (15.7%) | 173 (22.4%) | 76 (20.6%) | 65 (14.5%) | 36 (17.8%) | 449 (17.5%) | 47 (15.5%) | 76 (21.1%) | 684 (18.1%) |
Regional | 3433 (20.7%) | 177 (20.6%) | 74 (21.4%) | 134 (26.0%) | 165 (21.4%) | 79 (21.4%) | 109 (24.3%) | 38 (18.8%) | 511 (20.0%) | 50 (16.5%) | 74 (20.5%) | 790 (20.9%) |
Distant | 7630 (46.0%) | 428 (49.7%) | 167 (48.3%) | 234 (45.4%) | 336 (43.5%) | 179 (48.5%) | 235 (52.3%) | 112 (55.4%) | 1225 (47.8%) | 174 (57.4%) | 160 (44.3%) | 1831 (48.4%) |
Unknown | 2459 (14.8%) | 118 (13.7%) | 54 (15.6%) | 66 (12.8%) | 98 (12.7%) | 35 (9.5%) | 40 (8.9%) | 16 (7.9%) | 376 (14.7%) | 32 (10.6%) | 51 (14.1%) | 475 (12.6%) |